Cerity Partners
INMB icon

Cerity Partners’s INmune Bio INMB Stock Holding History

Cerity Partners’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.9K Buy
+14,042
New +$20K ﹤0.01% 3191

Other funds holding INMB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cerity Partners's INMB Position: Q1 2026 in Review

Cerity Partners opened a new position in INmune Bio (INMB) in Q1 2026: 14,042 shares worth $15.9K. The stake represents ﹤0.01% of the portfolio and ranks #3191 among its holdings.

82 funds tracked by Wall St. Rank hold INMB as of Q1 2026.

  • Cerity Partners held 14,042 shares of INmune Bio worth $15.9K as of Q1 2026.
  • INmune Bio was a new Cerity Partners position in Q1 2026.
  • INmune Bio made up ﹤0.01% of Cerity Partners's portfolio in Q1 2026, its #3191 holding.
  • 82 funds tracked by Wall St. Rank held INmune Bio as of Q1 2026.

Based on Cerity Partners's 13F filing for Q1 2026, filed 15 May 2026.